Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates: An example from patient populations in trials of human immunodeficiency virus infection

American Journal of Epidemiology

Volumn 144, Issue 11, 1996, Pages 1074-1085

  Ioannidis, John P A ^a   Cappelleri, Joseph C ^b   Schmid, Christopher H ^b,c   Lau, Joseph ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; latency; models, statistical; randomized controlled trials; study design; survival

Indexed keywords

ACICLOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; PLACEBO; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; EPIDEMIC; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCUBATION TIME; LATENT VIRUS INFECTION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; POPULATION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 0029809569     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008881     Document Type: Article

References (50)

1. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-19.
2. Bailey KR. Generalizing the results of randomized clinical trials. Control Clin Trials 1994;15:15-23.
3. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(RR-17):1-19.
4. Brookmeyer R, Gail MH, eds. AIDS epidemiology: a quantitative approach. New York, NY: Oxford University Press, 1994.
5. Brookmeyer R, Goedert JJ. Censoring in an epidemic with an application to hemophilia-associated AIDS. Biometrics 1989; 45:325-35.
6. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.
7. Ding Y. Computing back-calculation estimates of AIDS epidemic. Stat Med 1995;14:1505-12.
8. Moore RD, Hidalgo J, Sugland BW, et al. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-16.
9. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990;263:402-6.
10. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii, 1984 through 1987. JAMA 1990;263:397-401.
11. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
12. Brookmeyer R, Liao J. Statistical modelling of the AIDS epidemic for forecasting health care needs. Biometrics 1990; 46:1151-63.
13. Rosenberg PS, Gail MH, Caroll RJ. Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med 1992;11:1633-55.
14. 6/1, AIDS, and death from AIDS? BMJ 1994;309:1535-7.
15. Niu MT, Jermano JA, Reichelderfer P, et al. Summary of the National Institutes of Health workshop on primary immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1993;9:913-24.
16. Keet IPM, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7: 51-7.
17. Dorrucci M, Rezza G, Vlahov D, et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. AIDS 1995;9:597-604.
18. Sinicco A, Fora R, Sciandra M, et al. Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993;6:575-81.
19. Mathsoft Inc. Mathcad 6.1, 1994.
20. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: a meta-analysis. Ann Intern Med 1995;122: 856-66.
21. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
22. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med 1992;326:437-43.
23. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-37.
24. Merigan TC, Amato DA, Balsey J, et al. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. Blood 1991;78:900-6.
25. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
26. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995;333:401-7.
27. Cooper DA, Pedersen C, Aiuti F, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. AIDS 1991;5:933-43.
28. Manucci PM, Gringeri A, Savidge G, et al. Randomized double-blind, placebo-controlled trial of twice daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. Br J Haematol 1994;86: 174-7.
29. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HTV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled trial. AIDS 1994;8:313-21.
30. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
31. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329:297-303.
32. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. Controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
33. Chin J, Mann J. Global surveillance and forecasting of AIDS. Bull World Health Organ 1989;67:1-7.
34. McIntosh MW. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 1996;15: 1713-28.
35. Smith GD, Song F, Sheldon RA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367-73.
36. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Meth Med Res 1993;2:173-92.
37. CLASP (Collaborative Low-Dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 women. Lancet 1994;343:619-29.
38. Boissel JP, Collet JP, Lievre M, et al. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993;22:356-63.
39. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HTV-seroconverted injecting drug users. AIDS 1992;6:421-6.
40. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
41. Thomas PA, Weisfuse IB, Greenberg AE, et al. Trends in the first ten years of AIDS in New York City. Am J Epidemiol 1993;137:121-33.
42. Gorham ED, Garland FC, Mayers DL, et al. CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion: findings in the US Navy and Marine Corps. Arch Intern Med 1993;153:869-76.
43. Holmberg SD, Conley LJ, Luby SP, et al. Do persons infected with human immunodeficiency virus (HIV) in recent years have rapid loss of CD4 lymphocytes? J Acquir Immune Defic Syndr 1995;9:291-6.
44. Galai N, Lepri AC, Vlahov D, et al. Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. Am J Epidemiol 1996; 143:278-82.
45. Ho D. Time to hit HIV: early, and hard. N Engl J Med 1995;333:450-1.
46. The DATRI 002 Study Team. Clinical, virologic and immunologic presentation of primary HTV-1 infection in individuals enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of zidovudine (DATRI 002). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 17-20, 1995.
47. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
48. Ioannidis JPA, Cappelleri JC, Lau J, et al. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996;10:255-62.
49. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
50. Giorgi JV. HIV pathogenesis and prognostic markers for HIV disease progression: update from the MACS. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28 to February 1, 1996.